ENLV Enlivex Therapeutics Ltd. logo

ENLV Enlivex Therapeutics Ltd.

Healthcare
$0.72-0.37%ClosedMarket Cap: $17.4M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

0.02

PEG

0.00

P/B

0.02

P/S

0.00

EV/EBITDA

-1.12

DCF Value

$-0.04

FCF Yield

-63.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

248.1%

ROA

53.1%

ROIC

-0.5%

Financials

View All
PeriodRevenueNet IncomeEPS
Q4 null$0.00$1.24B$
FY null$0.00$1.24B$
Q3 null$0.00$-2.2M$
Q2 null$0.00$-1.9M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$15.00

Target (Median)

$15.00

Target Range

$15.00 - $15.00

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2026-04-07
HC Wainwright & Co.Buy
2026-01-12
D. Boral CapitalHold
2025-11-24
D. Boral CapitalBuy
2025-10-29
D. Boral CapitalBuy
2025-09-26

Trading Activity

Insider Trades

View All
Shlosberger Shacharofficer: Chief Financial Officer
SellWed Mar 18
Shlosberger Shacharofficer: Chief Financial Officer
SellWed Mar 18
Shlosberger Shacharofficer: Chief Financial Officer
SellWed Mar 18
Shlosberger Shacharofficer: Chief Financial Officer
SellWed Mar 18
Shlosberger Shacharofficer: Chief Financial Officer
SellWed Mar 18

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

IL

Exchange

Beta

1.49

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

Peers